-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – VB-1953 in Acne Vulgaris
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VB-1953 in Acne Vulgaris report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VB-1953 in Acne Vulgaris Drug Details: VB-1953 is under development for the...
-
Product Insights
Dermatomycoses – Drugs In Development, 2023
Global Markets Direct’s, ‘Dermatomycoses - Drugs In Development, 2023’, provides an overview of the Dermatomycoses pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dermatomycoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Dermatophytosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Dermatophytosis - Drugs In Development, 2023’, provides an overview of the Dermatophytosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dermatophytosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Non-infectious Uveitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Non-infectious Uveitis - Drugs In Development, 2023’, provides an overview of the Non-infectious Uveitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non-infectious Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Dermatological Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Dermatological Disorders - Drugs In Development, 2023’, provides an overview of the Dermatological Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dermatological Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Otitis Media – Drugs In Development, 2023
Global Markets Direct’s, ‘Otitis Media - Drugs In Development, 2023’, provides an overview of the Otitis Media pipeline landscape. The report provides comprehensive information on the therapeutics under development for Otitis Media, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Uveitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Uveitis - Drugs In Development, 2023’, provides an overview of the Uveitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Mycoses – Drugs In Development, 2023
Global Markets Direct’s, ‘Mycoses - Drugs In Development, 2023’, provides an overview of the Mycoses pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mycoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – besifloxacin
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry besifloxacin Drug Details Besifloxacin is under development for the treatment of facial Gram negative...